Table 5.
Details for ALL patients who developed myelotoxicity at least twice during the study (n = 13)*
| Patient no. | WBC (×109 l−1) | ANC (×109 l−1) | PLT (×109 l−1) | XO A1936G | A2107G | TPMT genotype | ITPA C94A | IVS2+21AC |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.7 | 0.86 | 356 | A/A | A/A | *1/*1 | C/C | A/A |
| 2 | 1.2 | 0.54 | 253 | A/A | A/A | *1/*1 | C/C | A/A |
| 3 | 2 | 1.24 | 196 | A/A | A/A | *1/*3C | C/C | A/C |
| 4 | 1.5 | 1.08 | 93 | A/A | A/A | *1/*1 | C/C | A/C |
| 5 | 2.5 | 1.84 | 203 | A/A | A/A | *1/*1 | C/C | A/A |
| 6 | 2.2 | 1.48 | 174 | A/A | A/A | *1/*1 | C/A | A/A |
| 7 | 1.7 | 0.3 | 253 | A/A | A/A | *1/*3C | C/C | A/A |
| 8 | 2.2 | 0.68 | 310 | A/A | A/A | *1/*1 | C/C | A/A |
| 9 | 2.3 | 0.98 | 213 | A/A | A/A | *1/*1 | C/C | A/A |
| 10 | 2.7 | 1.81 | 133 | A/A | A/A | *1/*1 | C/C | C/C |
| 11 | 1.3 | 0.83 | 232 | A/A | A/A | *1/*1 | C/C | A/A |
| 12 | 3 | 1.26 | 104 | A/A | A/A | *1/*1 | C/C | A/A |
| 13 | 1.4 | 0.94 | 144 | A/A | A/A | *1/*1 | C/C | A/A |
*
Values for WBC, ANC, PLT, and Hb are the lowest recorded during the study. WBC, white blood cell count; ANC, absolute neutrophil count; PLT, platelet count; ALL, acute lymphoblastic leukaemia; XO, xanthine oxidase; TPMT, thiopurine S-methyl transferase; ITPA, inosine triphosphatase. Mutations are highlighted in bold.